Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
scfDNA + polyethylenimine is an experimental DNA nanocarrier designed to mimic the proinflammatory effects of placental cell-free DNA (cfDNA) observed during pregnancy. It consists of a synthetic mimic of fetal cfDNA (scfDNA) complexed with the cationic polymer polyethylenimine (PEI) to facilitate cytosolic delivery. The drug targets the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway in monocytes and macrophages. By activating the cGAS-STING-IRF signaling axis, it induces a proinflammatory phenotype in tumor-associated macrophages (TAMs), potentially overcoming the immunosuppressive tumor microenvironment. This pregnancy-inspired approach is being developed as a strategy for cancer immunotherapy, specifically for reprogramming myeloid cells within the tumor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on scfDNA + polyethylenimine.